Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 3
2018 2
2019 2
2020 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
CD4+ Th1 to the rescue in HER-2+ breast cancer.
Lowenfeld L, Xu S, Czerniecki BJ. Lowenfeld L, et al. Oncoimmunology. 2018 May 2;8(10):e1078062. doi: 10.1080/2162402X.2015.1078062. eCollection 2019. Oncoimmunology. 2018. PMID: 31646065 Free PMC article.
Optimizing dendritic cell-based approaches for cancer immunotherapy.
Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Among authors: lowenfeld l. Yale J Biol Med. 2014 Dec 12;87(4):491-518. eCollection 2014 Dec. Yale J Biol Med. 2014. PMID: 25506283 Free PMC article. Review.
Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.
Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ. Rosemblit C, et al. Among authors: lowenfeld l. Oncotarget. 2018 May 1;9(33):23058-23077. doi: 10.18632/oncotarget.25208. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796172 Free PMC article.
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.
Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ. Lowenfeld L, et al. Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13. Clin Cancer Res. 2017. PMID: 27965306 Free article. Clinical Trial.
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.
Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Lowenfeld L, et al. Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017. Oncoimmunology. 2016. PMID: 28932627 Free PMC article.
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Datta J, et al. Among authors: lowenfeld l. Breast Cancer Res. 2015 May 23;17(1):71. doi: 10.1186/s13058-015-0584-1. Breast Cancer Res. 2015. PMID: 25997452 Free PMC article.
14 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page